Monoclonal antibodies (mAbs) make up an important class of biotherapeutics undergoing significant growth in the pharmaceutical industry today. Currently, more than 30 mAbs have been approved for use in treatment of a number of indications ranging from various forms of cancer to autoimmune and infectious diseases.
This technical note describes the comprehensive characterization of a representative monoclonal antibody Trastuzumab (Herceptin), illustrating the benefits of CESI coupled with high resolution mass spectrometry.
To download your copy of this application note complete the form opposite.
Registrants for this application note are covered by the Eclipse Business Media Privacy Policy.
Eclipse Business Media Ltd, Regd in England, No. 06513189, Woodview, Bull Lane Industrial Estate, Sudbury, CO10 0FD, United Kingdom, T +44 (0)161 818 7434, info@sepscience.com
Eclipse Business Media Ltd needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy or contact privacy@labxmediagroup.com
Copyright © 2025. All rights reserved